MorphoSys AG Reports Results for the First Three Months of 2015
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys AG Reports Results for the First Three Months of 2015
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
First Quarter Positively Impacted by One-Off Effects Relating to MOR202
Conference call (in English) today at 2:00pm CEST (1:00pm GMT/8:00am EST)
MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX, OTC: MPSYY) today
announced its financial results for the three months ending 31 March 2015. Group
revenues increased to EUR 70.4 million (Q1 2014: EUR 15.9 million). The increase
is attributable to revenue booked in connection with the ending of the
collaboration with Celgene on MorphoSys's proprietary drug candidate MOR202.
This comprised the full realization of deferred revenues from an up-front
payment received from Celgene in 2013 together with a one-time termination
payment. Earnings before interest and taxes (EBIT) amounted to EUR 52.8 million
(Q1 2014: EUR 1.4 million). On 31 March 2015, MorphoSys held cash and cash
equivalents, marketable securities, and financial assets classified as loans and
receivables of EUR 349.7 million in comparison to EUR 352.8 million on 31
December 2014.
| In EURO million* | Q1 2015 | Q1 2014 |
+-------------------------------------------+---------+---------+
| | | |
+-------------------------------------------+---------+---------+
| | | |
| | | |
| Group Revenues | 70.4 | 15.9 |
+-------------------------------------------+---------+---------+
| Total Operating Expenses | 17.7 | 14.5 |
+-------------------------------------------+---------+---------+
| Other Income/Expenses | 0.03 | 0.03 |
+-------------------------------------------+---------+---------+
| Earnings Before Interest and Taxes - EBIT | 52.8 | 1.4 |
+-------------------------------------------+---------+---------+
| Consolidated Net Profit | 40.9 | 1.1 |
+-------------------------------------------+---------+---------+
| Total EPS, diluted, in EURO | 1.55 | 0.04 |
+-------------------------------------------+---------+---------+
| | | |
+-------------------------------------------+---------+---------+
* Differences due to rounding
Highlights of the First Quarter 2015
* MorphoSys and Emergent BioSolutions initiated a phase 1 clinical trial in
prostate cancer patients with the bi-specific antibody MOR209/ES414. The
open-label phase 1 clinical trial will be conducted in clinical centers in
the US and Australia with planned enrollment of up to 130 patients.
* Upon publication of the 2014 annual financial results, MorphoSys provided an
overview of the 2015 development plan for its proprietary portfolio. Among
others, MorphoSys plans to initiate two phase 2 clinical trials in the
second half of 2015 to evaluate MOR208 in combination with lenalidomide and
bendamustine in diffuse large B-cell lymphoma.
* MorphoSys and Celgene mutually agreed to end their collaboration to co-
develop and co-promote MOR202. MorphoSys will continue as planned with the
clinical development of the compound, which is currently in a MorphoSys-
sponsored phase 1/2a trial in relapsed or refractory multiple myeloma
patients. The first clinical data will be presented at the Annual Meeting of
the American Society of Clinical Oncology at the end of May/early June.
* With the end of the collaboration with Celgene on MOR202, MorphoSys updated
its financial guidance for the current financial year and announced that it
expects revenues for the 2015 financial year in the range of EUR 101 million
to EUR 106 million (previous guidance: EUR 58 million to EUR 63 million) and
earnings before interest and taxes (EBIT) in the range of EUR 9 million to
EUR 16 million (previous guidance: a loss before interest and taxes of EUR
20 million to EUR 30 million).
* MorphoSys announced its nomination of three new Supervisory Board
candidates, Ms. Wendy Johnson, Mr. Klaus Kühn, and Dr. Frank Morich, for
election at the Annual General Meeting on 8 May 2015.
* Shortly after the end of the first quarter of 2015, MorphoSys announced the
achievement of a clinical milestone with the initiation of a phase 2 study
of the antibody guselkumab in psoriatic arthritis by its partner Janssen
Biotech.
* At the end of the first quarter of 2015, MorphoSys's product pipeline
comprised a total of 95 therapeutic antibodies, including 23 clinical
programs. Three partnered programs are currently in phase 3 trials.
"We have a very clear roadmap for our proprietary product portfolio in 2015
focusing on how we will advance MOR209/ES414 together with our partner Emergent
BioSolutions as well as MOR208 and MOR202 for our own account", commented Dr.
Simon Moroney, Chief Executive Officer of MorphoSys AG. "With MOR209/ES414, the
fourth candidate in our growing proprietary portfolio of compounds has entered
clinical development, thereby bringing the total number of clinical programs in
our pipeline to 23."
"The financial performance in the first quarter of 2015 was significantly
influenced by the termination agreement with Celgene and the resulting one-off
effects. This notwithstanding, MorphoSys has made a solid start to 2015 and the
Company is well positioned to meet its increased financial goals for the full
year," stated Jens Holstein, Chief Financial Officer of MorphoSys AG.
Financial Review for the First Three Months of 2015 (IFRS)
Group revenues for the first three months of 2015 amounted to EUR 70.4 million
(Q1 2014: EUR 15.9 million). This rise was primarily the result of the
termination of the cooperation with Celgene for the co-development and co-
promotion of MOR202 and the subsequent recognition of the respective deferred
revenues. The Proprietary Development segment recorded revenues of EUR 59.4
million (Q1 2014: EUR 4.1 million). These revenues originated mainly from the
termination of the contract with Celgene. Revenues in the Partnered Discovery
segment comprised EUR 10.5 million in funded research and licensing fees (Q1
2014: EUR 10.9 million) and EUR 0.5 million in success-based payments (Q1 2014:
EUR 0.9 million).
Total operating expenses for the first three months of 2015 amounted to EUR
17.7 million (Q1 2014: EUR 14.5 million). Total research and development
expenses were EUR 14.7 million (Q1 2014: EUR 11.2 million). R&D expenses
consisted mainly of personnel expenses and expenses for external laboratory
services. Investment in proprietary product and technology development amounted
to EUR 10.4 million (Q1 2014: EUR 7.3 million). General and administrative
expenses decreased to EUR 3.0 million (Q1 2014: EUR 3.3 million) driven by lower
expenses for personnel and for external services.
Earnings before interest and taxes (EBIT) amounted to EUR 52.8 million (Q1
2014: EUR 1.4 million) resulting from the full realization of deferred revenues
from an up-front payment received by Celgene. Proprietary Development showed a
segment EBIT of EUR 49.7 million (Q1 2014: EUR -2.6 million) while the Partnered
Discovery segment generated an EBIT of EUR 5.8 million (Q1 2014: EUR 6.9
million).
For the first three months of 2015, MorphoSys showed a consolidated net profit
for the Group of EUR 40.9 million (Q1 2014: net profit of EUR 1.1 million). The
resulting diluted net profit per share for the three months ending 31 March
2015 amounted to EUR 1.55 (Q1 2014: 0.04 EUR).
On 31 March 2015, the Company held cash and cash equivalents, marketable
securities, and financial assets (classified in the balance sheet in the
category "loans and receivables") of EUR 349.7 million in comparison to EUR
352.8 million on 31 December 2014. Net cash inflows from operating activities
amounted to EUR 2.7 million in the first three months of 2015 (Q1 2014: outflow
of EUR 7.7 million). The number of shares issued totaled 26,462,834 on 31 March
2015, of which 26,011,944 were outstanding (31 December 2014: 26,456,834 total
shares and 26,005,944 shares outstanding).
Outlook for 2015
On 26 March 2015, MorphoSys updated its financial guidance for the fiscal year
2015 as a result of the termination of the co-development and co-promotion
agreement for MOR202 with Celgene. The Company now expects revenues for the
2015 financial year in the amount of EUR 101 million to EUR 106 million (up from
previously EUR 58 million to EUR 63 million). Based on management's current
planning, proprietary R&D expenses are expected to increase to a range of EUR
56 million to EUR 63 million (previously EUR 48 million to EUR 58 million). The
Company now expects earnings before interest and taxes (EBIT) of approximately
EUR 9 million to EUR 16 million in 2015 (previously a loss of EUR 20 million to
EUR 30 million).
MorphoSys will hold a public conference call today at 02:00 p.m. CEST (08:00
a.m. EST, 01:00 p.m. GMT) to present the Q1 Results 2015 and report on current
developments.
Dial-in number for the analyst conference call (in English) at 02:00 pm CEST;
01:00 pm GMT; 08:00 am EST (listen-only):
Germany: +49 (0) 89 2444 32975
For UK residents: +44 (0) 20 3003 2666
For US residents: +1 202 204 1514
Please dial in 10 minutes before the beginning of the conference.
The speech and a transcript of the conference call will be made available at
http://www.morphosys.com.
The complete 1st Interim Report 2015 (January - March) is available on our
website (HTML and PDF): http://www.morphosys.com/FinancialReports
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 90 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit http://www.morphosys.com.
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®
and 100 billion high potentials® are registered trademarks of MorphoSys AG.
Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary
of MorphoSys AG.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Mario Brkulj
Associate Director Corporate Communications & IR
Alexandra Goller
Manager Corporate Communications & IR
Jessica Rush
Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
investors(at)morphosys.com
1st Interim Report 2015:
http://hugin.info/130295/R/1918589/686619.pdf
Media Release (PDF):
http://hugin.info/130295/R/1918589/686617.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via GlobeNewswire
[HUG#1918589]
Unternehmensinformation / Kurzprofil:
Datum: 05.05.2015 - 07:00 Uhr
Sprache: Deutsch
News-ID 390725
Anzahl Zeichen: 13830
contact information:
Town:
Martinsried / Munich
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 123 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys AG Reports Results for the First Three Months of 2015"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
